Vaccines for SARS coronavirus 2 and the new normal in vaccinology – Wiley

Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) causes an acute infection that is controlled by the immune response. The virus has a dominant surface protein that is highly immunogenic and it can be presumed that neutralising antibodies will prove to be the correlate of protection, supported by cellmediated immunity.1 It should therefore be straightforward to produce a vaccine against this novel virus.
This perspective has turned out to be true, but it is the pace with which the vaccines…

Click here to view the original article.